AstraZeneca Pharma India (506820) Q1 24/25 earnings summary

Executive summary

• Total income for the quarter ended 30 June 2024 was Rs 3,958.7 million, up from Rs 3,918.6 million in the previous quarter and Rs 3,035.7 million year-over-year.

• Net loss after tax for the quarter was Rs 117.9 million, compared to a profit of Rs 394.8 million in the previous quarter and Rs 538.6 million in the same quarter last year.

Financial highlights

• Revenue from operations for the quarter was Rs 3,875.2 million, compared to Rs 3,832.0 million in the previous quarter and Rs 2,954.7 million year-over-year.

• Profit before exceptional items and tax was Rs 424.0 million, down from Rs 543.6 million in the previous quarter and Rs 714.0 million year-over-year.

• Exceptional expense of Rs 575.6 million related to manufacturing site closure led to a pre-tax loss of Rs 151.6 million.

• Earnings per share (basic and diluted) for the quarter was negative Rs 4.72, compared to Rs 15.79 in the previous quarter and Rs 21.54 year-over-year.

Outlook and guidance

• The exit from the manufacturing site is expected to take more than 12 months, with ongoing efforts to find a buyer.